c-erb-b2/int-2 amplification appears faster in breast-cancer patients receiving second-line endocrine treatment

International Journal of Cancer

Volumn 69, Issue 4, 1996, Pages 273-277

  Lönn, Ulf ^a,b   Lönn, Sigrid ^a   Ingelman Sundberg, Henrik ^b   Nilsson, Bo ^b   Stenkvist, Björn ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; PROGESTERONE; TAMOXIFEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; NEEDLE BIOPSY; ONCOGENE C ERB; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; BREAST NEOPLASMS; FEMALE; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTORS; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGESTERONE; PROTO-ONCOGENE PROTEINS; TAMOXIFEN; TESTOSTERONE;

EID: 0029800395     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960822)69:4<273::AID-IJC6>3.0.CO;2-U     Document Type: Article

References (11)

1. ALI, I., MERLO, G., CALLAHAN, R. and LIDEREAU, R., The amplification unit on chromosome 11q13 in aggressive primary human breast tumors entails the bcl-1, int-2 and hst loci. Oncogene, 4, 89-92 (1989).
2. CLARK, G. and MCGUIRE, W., Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res., 51, 944-948 (1991).
3. FEARON, E. and VOGELSTEIN, B., A genetic model for colorectal tumorigenesis. Cell, 61, 759-767 (1990).
4. FIDLER, I. and RADINSKY, R., Genetic control of cancer metastasis. Editorial. J. nat. Cancer Inst., 82, 166 (1990).
5. FRYE, R., BENZ, C. and LIU, E., Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene, 4, 1153-1157 (1989).
6. LÖNN, U., LÖNN, S., NILSSON, B. and STENKVIST, B., Breast cancer: prognostic significance of c-erb-B2 and int-2 amplification compared with DNA ploidy, S-phase fraction, and conventional clinicopathological features. Breast Cancer Res. Treat., 29, 237-245 (1994).
7. LÖNN, U., LÖNN, S., NYLEN, U. and STENKVIST, B., Appearance and detection of multiple copies of the mdr-1 gene in clinical samples of mammary carcinoma. Int. J. Cancer, 51, 682-686 (1992).
8. NICOLSON, G., Tumor instability, diversification and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res., 47, 1473-1287 (1987).
9. NOONAN, K., BECK, C., HOLZMAYER, T., CHIN, J., WUNDER, J., ANDRULIS, I., GAZDAR, A., WILLMAN, C., GRIFFITH, B., HOFF, D. and RONINSON, I., Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumours by polymerase chain reaction. Proc. nat. Acad. Sci. (Wash.), 87, 7160-7164 (1990).
10. PERREN, T., c-ErbB2 oncogene as a prognostic marker in breast cancer. Brit. J. Cancer, 63, 328-332 (1991).
11. PETO, R., PIKE, M., ARMITAGE, P., BRESLOW, N., COX, D., HOWARD, S., MANTEL, M., MCPHERSON, K., PETO, J. and SMITH, P., Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Brit. J. Cancer, 35, 1-39 (1977).